Novartis booth at AACR 2026
Biotech

Novartis drops ph. 2-stage radioligand therapy over poor data

Novartis CEO Vas Narasimhan told Fierce that the company’s commitment to radioligand therapies “remains completely unchanged.”
James Waldron Jul 21, 2026 8:18am
light bulb idea innovation

Why Novartis CEO ended his ADC holdout for $1.5B Myricx deal

Jul 21, 2026 1:26pm
Panther Rare Pharmacy

De-risking rare disease launches: precision beats scale

Brought to you by PANTHERx® Rare Pharmacy
jupiter and its moons

Jupiter enters psychedelics space with $100M deal for MDMA drug

Jul 21, 2026 10:00am
shutterstock2729915667png

Understanding Agentic AI in Clinical Development

Brought to you by Syneos Health
Stop sign and red lights at traffic intersection

Agios says adios to sickle cell program over lackluster data

Jul 21, 2026 8:30am
More News

Lupin seeds US spinout with cash, clinical-stage cancer assets

Jul 21, 2026 8:20am

New center launches for personalized genetic therapies

Jul 21, 2026 8:00am

Why US biotech Axiom is starting its IPO journey in Hong Kong

Jul 21, 2026 7:02am

BMS, Nvidia aim for ‘most powerful AI factory in life sciences’

Jul 20, 2026 10:30am